Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of the Quantum Blue® reader Point-of-Care system versus ELISA technique for therapeutic drug monitoring of Infliximab levels
Vasilije Novakovic, Samire Abdija, Pia Bükmann Larsen, et al.
Clinical Biochemistry (2019) Vol. 74, pp. 73-75
Closed Access | Times Cited: 16

Showing 16 citing articles:

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn’s disease patients
Lívia Moreira Genaro, Juliana Carron, Marina Moreira de Castro, et al.
International Journal of Immunopathology and Pharmacology (2025) Vol. 39
Open Access
Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point of Care Testing in Inflammatory Bowel Disease: Results of a Pragmatic Trial
Peter Bossuyt, Lieven Pouillon, Sophie Claeys, et al.
Journal of Crohn s and Colitis (2021) Vol. 16, Iss. 2, pp. 199-206
Closed Access | Times Cited: 33
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
C. Krieckaert, Borja Hernández‐Breijo, Johanna Elin Gehin, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002216-e002216
Open Access | Times Cited: 15
Quantification of Infliximab and Adalimumab in Human Plasma by a Liquid Chromatography Tandem Mass Spectrometry Kit and Comparison with Two ELISA Methods
Camille Tron, F. Lemaı̂tre, Pauline Bros, et al.
Bioanalysis (2022) Vol. 14, Iss. 11, pp. 831-844
Open Access | Times Cited: 12
Enhancing Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Comparative Analysis of Rapid Point-of-Care Infliximab, Adalimumab and Anti-Drug Antibodies’ Determination against ELISA
Francisco José Toja-Camba, Laura García‐Quintanilla, Lorena Rodríguez-Martínez, et al.
Pharmaceutics (2023) Vol. 15, Iss. 11, pp. 2615-2615
Open Access | Times Cited: 6
Performance of a New Rapid Point-of-Care Test for Infliximab Levels in Patients with Inflammatory Bowel Disease: A Comparison to ELISA
Teresa Valdés-Delgado, A Aguado-Paredes, Vicente Merino‐Bohórquez, et al.
Digestive Diseases and Sciences (2023) Vol. 69, Iss. 1, pp. 228-234
Open Access | Times Cited: 4
Infliximab monitoring in Crohn’s disease: a neural network approach for evaluating disease activity and immunogenicity
Luís Eduardo Miani Gomes, Lívia Moreira Genaro, Marina Moreira de Castro, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 1
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies
Konstantinos Papamichael, Adam S. Cheifetz
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 12, pp. 1423-1431
Closed Access | Times Cited: 7
Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay
Eva A. van Aalen, Ivar R. de Vries, Eva T. L. Hanckmann, et al.
Sensors & Diagnostics (2023) Vol. 2, Iss. 6, pp. 1492-1500
Open Access | Times Cited: 2
Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
Anna Pękala, Rafał Filip, David Aebisher
Journal of Clinical Medicine (2021) Vol. 10, Iss. 12, pp. 2653-2653
Open Access | Times Cited: 6
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access
Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study
Erica Bonazzi, Daria Maniero, Greta Lorenzon, et al.
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2140-2140
Open Access
Lateral flow test versus enzyme‐linked immunosorbent assay to measure infliximab trough concentrations: A head‐to‐head comparison
Marleen Bouhuys, Margreet Wessels, Willemien de Vries, et al.
Journal of Pediatric Gastroenterology and Nutrition (2024)
Open Access
Evaluating the Accuracy and Clinical Utility of AFIAS-10 Point of Care Versus Enzyme-Linked Immunosorbent Assay in Therapeutic Drug Monitoring of Infliximab and Adalimumab
Carles Iniesta Navalón, Manuel Ríos-Saorín, Rebeca Añez-Castaño, et al.
Therapeutic Drug Monitoring (2024)
Closed Access
Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study
Anna Pękala, Rafał Filip
Journal of Clinical Medicine (2021) Vol. 10, Iss. 22, pp. 5311-5311
Open Access | Times Cited: 1
Page 1

Scroll to top